<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Guillain-Barré syndrome in children: Epidemiology, clinical features, and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Guillain-Barré syndrome in children: Epidemiology, clinical features, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Guillain-Barré syndrome in children: Epidemiology, clinical features, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eppie Yiu, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas R Nordli, Jr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeremy M Shefner, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The acute immune-mediated polyneuropathies are classified under the eponym Guillain-Barré syndrome (GBS) after some of the authors of early descriptions of the disease. GBS is one of the most common causes of acute, acquired weakness and is often provoked by a preceding infection. GBS may be complicated in some cases by respiratory failure and autonomic dysfunction.</p><p>This epidemiology, clinical features, and diagnosis of GBS in children will be reviewed here.</p><p>Other aspects of GBS in children are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6204.html" rel="external">"Guillain-Barré syndrome in children: Treatment and prognosis"</a>.)</p><p>GBS in adults is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5137.html" rel="external">"Guillain-Barré syndrome in adults: Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5172.html" rel="external">"Guillain-Barré syndrome in adults: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H21329582"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of Guillain-Barré syndrome (GBS) is discussed here briefly and reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5137.html" rel="external">"Guillain-Barré syndrome in adults: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p>One proposed mechanism for GBS is that an antecedent infection evokes an immune response, which in turn cross-reacts with peripheral nerve components because of the sharing of cross-reactive epitopes (molecular mimicry). The end result is an acute polyneuropathy. This immune response can be directed toward the myelin or the axon of peripheral nerve. The main lesions of GBS are acute inflammatory demyelinating polyradiculoneuropathy and, particularly in patients with <em>Campylobacter</em>-associated disease, acute axonal degeneration. (See  <a class="medical medical_review" href="/z/d/html/5137.html" rel="external">"Guillain-Barré syndrome in adults: Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5137.html" rel="external">"Guillain-Barré syndrome in adults: Pathogenesis, clinical features, and diagnosis", section on 'Pathogenesis'</a>.)</p><p>Antecedent infections are common with GBS and are thought to trigger the immune response that leads to acute polyneuropathy. Approximately two-thirds of patients give a history of an antecedent respiratory tract or gastrointestinal infection. <em>Campylobacter</em> infection is the most commonly identified precipitant of GBS and can be demonstrated in as many as 30 percent of cases. Other precipitants include cytomegalovirus, Epstein-Barr virus, <em>Mycoplasma pneumoniae</em>, respiratory syncytial virus, and influenza-like illnesses [<a href="#rid1">1-6</a>]. GBS can also occur in association with HIV infection, predominantly in those who are not profoundly immunocompromised. A small percentage of patients develop GBS after another triggering event such as immunization, surgery, trauma, or bone-marrow transplantation. (See  <a class="medical medical_review" href="/z/d/html/5137.html" rel="external">"Guillain-Barré syndrome in adults: Pathogenesis, clinical features, and diagnosis", section on 'Antecedent events'</a>.)</p><p>While GBS has followed vaccinations, the small risk of GBS associated with influenza vaccination, of approximately one to two excess cases of GBS per million people vaccinated, is substantially less than the overall health risk posed by naturally occurring influenza. Furthermore, the risk of GBS following influenza infection is several times greater than the risk following influenza vaccination. (See  <a class="medical medical_review" href="/z/d/html/5137.html" rel="external">"Guillain-Barré syndrome in adults: Pathogenesis, clinical features, and diagnosis", section on 'Vaccinations'</a>.)</p><p>The available evidence suggests that there is no increased risk of GBS associated with the H1N1 influenza vaccine in children [<a href="#rid7">7-9</a>]. The association between vaccinations against coronavirus disease 2019 (COVID-19) and GBS are presented separately. (See  <a class="medical medical_review" href="/z/d/html/5137.html" rel="external">"Guillain-Barré syndrome in adults: Pathogenesis, clinical features, and diagnosis", section on 'Vaccinations'</a> and  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines", section on 'Guillain-Barré syndrome'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>In the post-polio era, GBS is the most common cause of acute flaccid paralysis in healthy infants and children [<a href="#rid10">10,11</a>]. GBS occurs worldwide with an annual incidence of 0.34 to 1.34 cases per 100,000 persons aged 18 years or less. [<a href="#rid12">12-14</a>]. While all age groups are affected, the incidence is lower in children than in adults. The incidence increases by approximately 20 percent with every 10-year increase in age beyond the first decade of life. GBS occurs rarely in children younger than two years of age but can occur even in infants [<a href="#rid15">15,16</a>]. There is a case report of congenital GBS in the neonate of an affected mother [<a href="#rid17">17</a>].</p><p>Males are affected approximately 1.5 times more often than females in all age groups.</p><p class="headingAnchor" id="H6"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>GBS is a clinical syndrome with a number of variant forms. In patients with acute inflammatory demyelinating polyradiculopathy (AIDP), the most common form of GBS, two-thirds develop the neurologic symptoms two to four weeks after what initially appears to be a benign febrile respiratory or gastrointestinal infection [<a href="#rid18">18,19</a>].</p><p class="headingAnchor" id="H695577847"><span class="h2">Neurologic symptoms</span><span class="headingEndMark"> — </span>The classic presentation of GBS begins with paresthesia in the toes and fingertips followed by lower extremity symmetric or modestly asymmetric weakness that may ascend over hours to days to involve the arms and, in severe cases, the muscles of respiration [<a href="#rid20">20,21</a>]. The predominant symptoms of GBS at presentation in children are pain and gait difficulty [<a href="#rid22">22</a>]. In preschool-aged children, the most common symptoms are refusal to walk and pain in the legs. Diagnosis may be delayed in this age group in the presence of these and other nonspecific symptoms such as meningism and irritability [<a href="#rid23">23</a>].</p><p>In a prospective series of 95 children with GBS, the most frequent initial symptoms were gait unsteadiness, neuropathic pain, and inability to walk, occurring in 45, 34, and 24 percent of cases, respectively [<a href="#rid24">24</a>]. By the peak of the illness, the frequency of symptoms was as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>79 percent had neuropathic pain.</p><p class="bulletIndent1"><span class="glyph">●</span>60 percent could not walk.</p><p class="bulletIndent1"><span class="glyph">●</span>51 percent had autonomic dysfunction.</p><p class="bulletIndent1"><span class="glyph">●</span>46 percent had cranial nerve involvement.</p><p class="bulletIndent1"><span class="glyph">●</span>24 percent could not use their arms.</p><p class="bulletIndent1"><span class="glyph">●</span>13 percent required mechanical ventilation.</p><p></p><p>Cranial neuropathy most commonly affects the facial nerves, causing bilateral facial weakness [<a href="#rid24">24,25</a>]. Pain typically involves the back and the legs [<a href="#rid26">26</a>].</p><p>Autonomic dysfunction occurs in approximately one-half of children with GBS and may include the following [<a href="#rid24">24,27,28</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A variety of cardiac dysrhythmias (asystole, bradycardia, persistent sinus tachycardia, and atrial and ventricular tachyarrhythmias)</p><p class="bulletIndent1"><span class="glyph">●</span>Orthostatic hypotension</p><p class="bulletIndent1"><span class="glyph">●</span>Transient or persistent hypertension</p><p class="bulletIndent1"><span class="glyph">●</span>Paralytic ileus</p><p class="bulletIndent1"><span class="glyph">●</span>Bladder dysfunction</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal sweating</p><p></p><p>Rare patients have central nervous system involvement [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Physical examination findings</span><span class="headingEndMark"> — </span>Physical examination typically reveals symmetric weakness with diminished or absent reflexes and gait abnormalities [<a href="#rid20">20,21</a>]. Sensory symptoms are usually "positive" (eg, pain or paresthesia, reflecting nerve irritability) rather than "negative" (eg, loss of sensation). Some cases present with initial proximal weakness, or less common findings such as sphincter disturbances, raising concerns about a possible spinal cord lesion.</p><p class="headingAnchor" id="H8"><span class="h2">Clinical course</span><span class="headingEndMark"> — </span>More than 90 percent of patients reach the nadir of their function within two to four weeks [<a href="#rid30">30</a>]. In a retrospective cohort of 421 children, the median time from symptom onset to nadir was eight days (interquartile range 5 to 13 days) [<a href="#rid27">27</a>]. Return of function occurs slowly, typically over weeks to months.</p><p>The clinical course of GBS in children is shorter than in adults and recovery is usually more complete [<a href="#rid31">31-34</a>]. In one large study, median time to recovery of independent walking was 36 days (IQR 20 to 61, range 2 to 423 days) [<a href="#rid27">27</a>]. In prospective studies, nearly all children regained the ability to walk at 6 and 12 months (90 and 96 percent, respectively) [<a href="#rid24">24,35</a>].</p><p class="headingAnchor" id="H9"><span class="h1">VARIANT FORMS OF GUILLAIN-BARRÉ SYNDROME</span><span class="headingEndMark"> — </span>Historically, GBS was considered a single disorder. It is now known to be a heterogeneous syndrome with several variant forms [<a href="#rid36">36,37</a>]. Acute inflammatory demyelinating polyradiculopathy (AIDP) is the most common type. Axonal forms of GBS are also well recognized. Each type of GBS has distinguishing clinical, pathophysiologic, and pathologic features [<a href="#rid38">38</a>]. The classic presentation of ascending paralysis is most common, but a number of atypical variants present with local or regional involvement of particular muscle groups or nerves [<a href="#rid36">36,37,39</a>]. Several have prominent cranial nerve involvement, including Miller Fisher syndrome (MFS), Bickerstaff brainstem encephalitis, polyneuritis cranialis, and pharyngeal-cervical-brachial weakness. Others include pure sensory neuropathy and acute pandysautonomia.</p><p class="headingAnchor" id="H10"><span class="h2">Acute inflammatory demyelinating polyneuropathy</span><span class="headingEndMark"> — </span>AIDP is the prototype of GBS and is the most common form in North America, Europe, and most of the developed world, where it accounts for about 85 to 90 percent of cases.</p><p class="headingAnchor" id="H507337468"><span class="h2">Acute axonal neuropathies</span><span class="headingEndMark"> — </span>These disorders are distinguished from AIDP by their more severe course, involvement of motor or motor and sensory nerves, and an electrophysiologic pattern suggesting axonal damage.</p><p class="headingAnchor" id="H11"><span class="h3">Acute motor axonal neuropathy</span><span class="headingEndMark"> — </span>Acute motor axonal neuropathy (AMAN) is a pure motor form of GBS. AMAN occurs mainly in northern China but is also a common form of GBS in other locations, including Japan, Mexico, and South America [<a href="#rid40">40-46</a>]. It is more common in developing nations, has a seasonal incidence, and is associated with a preceding <em>Campylobacter jejuni</em> infection. In a series of 31 Japanese children with GBS classified by electrophysiologic criteria, AIDP, AMAN, and unclassified GBS were seen in 11, 15, and 5 children (35, 48, and 16 percent, respectively) [<a href="#rid45">45</a>].</p><p>The presenting clinical features and recovery are similar to those of AIDP [<a href="#rid47">47</a>]. However, more patients have respiratory failure requiring assisted ventilation.</p><p class="headingAnchor" id="H12"><span class="h3">Acute motor-sensory axonal neuropathy</span><span class="headingEndMark"> — </span>Acute motor-sensory axonal neuropathy (AMSAN) resembles the motor axonal variant but has more sensory symptoms. The course tends to be prolonged and severe [<a href="#rid48">48,49</a>]. The pathology is predominantly axonal lesions of both motor and sensory nerve fibers. This form of GBS is uncommon in children.</p><p class="headingAnchor" id="H4024413162"><span class="h2">GQ1b syndromes</span><span class="headingEndMark"> — </span>Some forms of GBS are characterized by eye movement abnormalities and ataxia rather than limb weakness and numbness. These forms are associated with frequent seropositivity to antibodies against the GQ1b ganglioside and include MFS, Bickerstaff encephalitis, and pharyngeal-cervical-brachial weakness [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H13"><span class="h3">Miller Fisher syndrome</span><span class="headingEndMark"> — </span>MFS is characterized by external ophthalmoplegia, ataxia, and muscle weakness with areflexia [<a href="#rid51">51,52</a>]. Incomplete forms include acute ophthalmoplegia without ataxia and acute ataxic neuropathy without ophthalmoplegia [<a href="#rid37">37</a>]. Cerebrospinal fluid findings and electrophysiologic features are similar to those in acute inflammatory demyelinating polyneuropathy. Brainstem auditory-evoked potentials demonstrate peripheral and central conduction defects [<a href="#rid34">34</a>]. GQ1b antibodies are frequently found in patients with MFS [<a href="#rid53">53</a>]. </p><p class="headingAnchor" id="H345309608"><span class="h3">Bickerstaff encephalitis</span><span class="headingEndMark"> — </span>Bickerstaff encephalitis is a brainstem encephalitis characterized by encephalopathy and hyperreflexia, in combination with such features of MFS as ophthalmoplegia and ataxia. It is not only clinically linked to MFS but is associated with anti-GQ1b antibodies and can respond to intravenous immunoglobulin (<a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a>) and plasma exchange [<a href="#rid54">54-56</a>].</p><p class="headingAnchor" id="H1798875183"><span class="h3">Pharyngeal-cervical-brachial weakness</span><span class="headingEndMark"> — </span>The pharyngeal-cervical-brachial variant of GBS is characterized by acute weakness of the oropharyngeal, neck, and shoulder muscles, with swallowing dysfunction [<a href="#rid57">57-59</a>]. Facial weakness may also be present. Strength and reflexes are usually normal in the lower extremities. This form of GBS may overlap with MFS [<a href="#rid58">58,60</a>]. It is thought to represent a localized form of axonal GBS [<a href="#rid37">37,57,58</a>]. Some patients with pharyngeal-cervical-brachial weakness have immunoglobulin G (IgG) autoantibodies to GT1a, GQ1b, or (less often) to GD1a.</p><p class="headingAnchor" id="H14"><span class="h2">Polyneuritis cranialis</span><span class="headingEndMark"> — </span>Patients with polyneuritis cranialis develop acute bilateral multiple cranial nerve involvement (eg, bilateral facial weakness, ocular signs, dysphagia, and dysphonia) without ataxia or limb weakness [<a href="#rid61">61</a>].</p><p>Cerebrospinal fluid findings and electrophysiologic features are similar to those of AIDP. Magnetic resonance imaging (MRI) with gadolinium may show postcontrast enhancement of the cranial nerve roots [<a href="#rid62">62,63</a>].</p><p class="headingAnchor" id="H345309167"><span class="h2">Other variants</span><span class="headingEndMark"> — </span>There are a number of additional uncommon variants of GBS, including the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute pandysautonomia, symptoms of which include diarrhea, vomiting, dizziness, abdominal pain, ileus, orthostatic hypotension, urinary retention, pupillary abnormalities, an invariant heart rate, decreased sweating, salivation, and lacrimation [<a href="#rid64">64</a>]. The deep tendon reflexes are absent or diminished and sensory symptoms may be present [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pure sensory GBS, with involvement of large sensory fibers leading to significant sensory ataxia [<a href="#rid66">66</a>]. The deep tendon reflexes are absent and there may be minor motor involvement. An association with antibodies to GD1b has been noted.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Facial diplegia and distal limb paresthesia [<a href="#rid60">60</a>]. This is considered a variant of acute inflammatory demyelinating polyneuropathy [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sixth nerve palsy and distal paresthesia [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Paraparesis, with weakness restricted to the legs at presentation [<a href="#rid57">57,67</a>]. A minority experiences some arm weakness over the course of the illness.</p><p></p><p class="headingAnchor" id="H15"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The initial diagnosis of GBS is based upon the clinical presentation. The typical clinical features of GBS are progressive, mostly symmetric or modestly asymmetric muscle weakness and absent or depressed deep tendon reflexes (see <a class="local">'Clinical features'</a> above). The weakness can vary from mild difficulty with walking to nearly complete paralysis of all extremity, facial, respiratory, and bulbar muscles. However, some GBS variants present with local or regional involvement of particular muscle groups or nerves, and several have prominent cranial nerve involvement; the variable initial presentations can hinder early diagnosis. (See <a class="local">'Variant forms of Guillain-Barré syndrome'</a> above.)</p><p>No single investigation can confirm or disprove the diagnosis of GBS, particularly early in its course. In a child with a compatible clinical presentation, the diagnosis is contingent on supporting evidence from the clinical examination, cerebrospinal fluid (CSF) analysis, electrodiagnostic studies, magnetic resonance imaging (MRI), and/or ancillary investigations (eg, serum immunoglobulin G [IgG] antibodies to GQ1b), with the exclusion of alternative diagnoses by the same means [<a href="#rid68">68</a>].</p><p>Supportive features include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>An elevated CSF protein (&gt;45 mg/dL) with a normal CSF white blood cell count (ie, albuminocytologic dissociation). (See <a class="local">'Cerebrospinal fluid'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the demyelinating forms of GBS, electrodiagnostic studies demonstrating abnormalities including motor conduction block, slowing of motor and sensory nerve conduction, temporal dispersion, and prolonged distal latencies. In the axonal forms of GBS, nerve conduction studies showing decreased amplitude of motor (and possibly sensory) responses, with normal conduction velocities. (See <a class="local">'Electrodiagnostic studies'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Contrast enhancement of the spinal nerve roots, cauda equina, or cranial nerves on MRI. (See <a class="local">'Magnetic resonance imaging'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Detection of serum IgG antibodies to GQ1b, supporting the diagnosis of the GBS variants Miller Fisher syndrome, Bickerstaff encephalitis, and pharyngeal-cervical-brachial weakness. (See <a class="local">'Antibodies'</a> below.)</p><p></p><p class="headingAnchor" id="H603783422"><span class="h2">Cerebrospinal fluid</span><span class="headingEndMark"> — </span>In patients with GBS, lumbar puncture often reveals an elevated CSF protein with a normal CSF white blood cell count. This finding, known as albuminocytologic dissociation, is present in up to 70 percent of patients with GBS overall [<a href="#rid69">69</a>]. In a study of 1231 patients from the International GBS Outcome Study, elevated CSF protein (&gt;0.45 g/L) was present in 56 percent of patients when assessed within the first three days from symptom onset and 86 percent when CSF was tested within seven days of onset [<a href="#rid37">37,69,70</a>]. The elevated protein may be due to increased permeability of the blood-nerve barrier at the level of the proximal nerve roots or increased intrathecal antibody synthesis. Higher CSF protein levels have been associated with a demyelinating subtype of GBS, proximal or global muscle weakness, and a poorer short- (less than four weeks), but not long-term outcome [<a href="#rid69">69</a>].</p><p>In a prospective series of 110 patients with GBS, initial CSF protein elevation varied from 45 to 200 mg/dL (0.45 to 2.0 g/L) in 73 percent of patients, but protein elevation as high as 1000 mg/dL (10 g/L) has been described [<a href="#rid70">70</a>].</p><p>A minority of patients with GBS have mildly elevated CSF cell counts. In the same series, the CSF cell count was &lt;5, 5 to 10, 11 to 30, and &gt;30 cells/mm<sup>3</sup> in 87, 9, 2, and 2 percent of patients, respectively [<a href="#rid70">70</a>].</p><p>Concurrent HIV infection or an alternative diagnosis (eg, Lyme disease, poliomyelitis, enterovirus 71 infection, West Nile virus, or malignancy) should be considered in children with acute flaccid paralysis who have a CSF cell count &gt;50/mm<sup>3</sup>.</p><p class="headingAnchor" id="H603783376"><span class="h2">Electrodiagnostic studies</span><span class="headingEndMark"> — </span>Electrodiagnostic studies are the most specific and sensitive tests for diagnosis of GBS and establish the underlying pathophysiology as either demyelinating or axonal. Performance of a detailed neurophysiologic study enables diagnosis of pediatric GBS in as many as 90 percent of cases during the first week of symptoms [<a href="#rid71">71</a>]. Changes are virtually universal by the second week of illness, by which time a definitive diagnosis can almost always be made. Electrodiagnostic studies are uncomfortable and can be technically challenging in small children; they should therefore be undertaken only by individuals with appropriate pediatric expertise. (See  <a class="medical medical_review" href="/z/d/html/5145.html" rel="external">"Overview of electromyography"</a> and  <a class="medical medical_review" href="/z/d/html/5142.html" rel="external">"Overview of nerve conduction studies"</a>.)</p><p>Peripheral nerve demyelination often primarily affects proximal nerve roots and the terminal segments of motor nerves and can be accompanied by conduction block [<a href="#rid24">24,71,72</a>]. In some cases, this results in unrecordable motor responses. It may not be possible, on neurophysiologic criteria, to distinguish this situation from extensive axonal degeneration. The prognostic implications of severely reduced compound muscle action potential (CMAP) amplitudes must therefore be interpreted with caution. When peripheral responses are unrecordable, a search for more proximal responses (such as those from stimulation of the phrenic or axillary nerves) may enable identification of a primarily demyelinating process. Electromyographic evidence of acute denervation is always suggestive of severe axonal injury and a worse prognosis [<a href="#rid71">71-73</a>].</p><p class="headingAnchor" id="H3392820"><span class="h2">Magnetic resonance imaging</span><span class="headingEndMark"> — </span>Spinal MRI with administration of gadolinium frequently shows enhancement of the spinal nerve roots and cauda equina during the first weeks after the onset of GBS in children [<a href="#rid74">74-76</a>]. The enhancement may be diffuse or predominantly involve the ventral (anterior) nerve roots and less often the dorsal (posterior) roots. In some cases, nerve root enhancement may be delayed and observed only on a repeat MRI. Enhancement of cranial nerve roots may also be seen in some cases, reflecting more diffuse nerve involvement [<a href="#rid76">76,77</a>].</p><p>Evidence from uncontrolled retrospective studies suggests that the sensitivity of contrast-enhanced spinal MRI for the diagnosis of childhood GBS is &gt;90 percent [<a href="#rid74">74-76</a>]. Nevertheless, spinal nerve root enhancement is a nonspecific finding that can be seen in a variety of disorders including polyradiculopathy related to HIV or cytomegalovirus infection, chronic inflammatory demyelinating polyneuropathy, acute flaccid myelitis, arachnoiditis, sarcoidosis, carcinomatous or lymphomatous meningitis, and certain metabolic diseases. Thus, the diagnosis of GBS cannot be made by MRI alone.</p><p class="headingAnchor" id="H603783536"><span class="h2">Antibodies</span><span class="headingEndMark"> — </span>Immune reactions directed against epitopes in Schwann cell surface membrane or myelin can cause the acute demyelinating form of GBS, while immune reactions against epitopes contained in the axonal membrane cause the acute axonal forms of GBS. Antibodies against GQ1b, a ganglioside component of nerve, are present in the vast majority of patients with Miller Fisher and similar syndromes. (See <a class="local">'Miller Fisher syndrome'</a> above and  <a class="medical medical_review" href="/z/d/html/5137.html" rel="external">"Guillain-Barré syndrome in adults: Pathogenesis, clinical features, and diagnosis", section on 'GQ1b syndromes'</a>.)</p><p>In clinical practice, commercially available testing for serum IgG antibodies to GQ1b is useful for the diagnosis of Miller Fisher syndrome, having a sensitivity of 85 to 90 percent. Antibodies to GQ1b may also be present in GBS with ophthalmoparesis, Bickerstaff encephalitis, and the pharyngeal-cervical-brachial GBS variant but not in disorders other than GBS [<a href="#rid53">53,78</a>].</p><p>Currently, laboratory testing for antibodies to glycolipids other than GQ1b is not performed routinely because of limited clinical utility.</p><p class="headingAnchor" id="H17"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Disorders of the central nervous system, peripheral nerve, neuromuscular junction, and muscle may have features that initially resemble GBS (<a class="graphic graphic_table graphicRef80040" href="/z/d/graphic/80040.html" rel="external">table 1</a>). However, consideration of the neurologic examination, clinical course, cerebrospinal fluid profile, and electrodiagnostic findings usually establish the diagnosis of GBS [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H603783766"><span class="h2">Chronic inflammatory demyelinating polyneuropathy</span><span class="headingEndMark"> — </span>There is a temporal continuum between acute inflammatory demyelinating polyneuropathy (AIDP), the demyelinating form of GBS, and chronic inflammatory demyelinating polyneuropathy (CIDP).</p><p class="bulletIndent1"><span class="glyph">●</span>AIDP is a monophasic subacute illness that reaches its nadir within three to four weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CIDP continues to progress or has relapses for longer than eight weeks. (See  <a class="medical medical_review" href="/z/d/html/5264.html" rel="external">"Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subacute inflammatory demyelinating polyneuropathy is the term used by some authors for disease that reaches its nadir between four and eight weeks [<a href="#rid79">79,80</a>].</p><p></p><p>This arbitrary temporal delineation of inflammatory demyelinating polyneuropathy can occasionally be difficult to ascertain in practice. Only observation of the patient over time can clarify whether the clinical course is that of AIDP or CIDP.</p><p>In addition to chronicity, other features may be useful to distinguish GBS (including AIDP) from CIDP:</p><p class="bulletIndent1"><span class="glyph">●</span>While the onset of GBS is usually easily identified, the precise onset of CIDP is typically less clear.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antecedent events are more frequent with GBS (where they occur in approximately 70 percent of cases) than with CIDP (where they are found in ≤30 percent of cases). (See  <a class="medical medical_review" href="/z/d/html/5137.html" rel="external">"Guillain-Barré syndrome in adults: Pathogenesis, clinical features, and diagnosis", section on 'Antecedent events'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Certain features are more consistent with an increased likelihood of CIDP in the first weeks after onset of symptoms, including three or more episodes of clinical deterioration, a mild disease course with retained ability to walk independently, and lack of cranial neuropathies [<a href="#rid81">81</a>].</p><p></p><p>Up to 2 percent of children initially diagnosed with AIDP will develop the chronic relapsing weakness of CIDP [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/z/d/html/5172.html" rel="external">"Guillain-Barré syndrome in adults: Treatment and prognosis", section on 'Approach to patients who relapse or worsen'</a>.)</p><p class="headingAnchor" id="H603783772"><span class="h2">Other polyneuropathies</span><span class="headingEndMark"> — </span>Acute polyneuropathies that may mimic GBS include those due to acute severe vitamin B1 deficiency, nitrous oxide-induced neuropathy, acute arsenic poisoning, n-hexane (in glue sniffing neuropathy), vasculitis, Lyme disease, tick paralysis, porphyria, sarcoidosis, leptomeningeal disease, paraneoplastic disease, and critical illness.</p><p>The combination of data from the clinical setting, appropriate screening laboratory tests (including thiamine, vitamin B12 and homocysteine levels, rheumatologic testing, Lyme titer, spot urine for porphyria), as well as electromyography with nerve conduction studies and cerebrospinal fluid analysis, are usually sufficient to rule out these other, much less common, causes of polyneuropathy. A spot urine test for porphobilinogen in a sample obtained at the time of symptoms will identify the majority of patients with acute porphyria. (See  <a class="medical medical_review" href="/z/d/html/7096.html" rel="external">"Acute intermittent porphyria: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p>Peripheral nerve vasculitis is a potentially life-threatening illness that can be difficult to diagnose. The pattern is that of a mononeuritis multiplex involving sensory and motor fibers in the distribution of individual peripheral nerves. Although the pathology of the disease is asymmetric, the clinical picture can mimic GBS with fairly symmetric ascending weakness when the vasculitis is rapidly progressive with confluent nerve involvement. Vasculitic neuropathies are rare in childhood. (See  <a class="medical medical_review" href="/z/d/html/8236.html" rel="external">"Clinical manifestations and diagnosis of vasculitic neuropathies"</a>.)</p><p class="headingAnchor" id="H603783778"><span class="h2">Spinal cord disorders</span><span class="headingEndMark"> — </span>Acute myelopathies due to spinal cord compression or acute transverse myelitis can be confused with GBS, since reflexes can be depressed in the acute stage of spinal cord disease. Early bowel and bladder dysfunction and a sensory level point to a myelopathy. Imaging with spine MRI is usually helpful in diagnosing acute myelopathy by demonstrating a focal spinal cord lesion.</p><p>Severe low back pain is common with GBS and frequently leads to imaging of the lumbar spine; prominent contrast enhancement of the nerve roots on MRI may occur in GBS. (See <a class="local">'Magnetic resonance imaging'</a> above.)</p><p class="headingAnchor" id="H603783784"><span class="h2">Neuromuscular junction disorders</span><span class="headingEndMark"> — </span>Diseases of the neuromuscular junction including botulism and myasthenia gravis can present with acute weakness, but without sensory signs or symptoms. Botulism is associated with large, unreactive pupils and constipation. Electromyography with repetitive nerve stimulation and appropriate laboratory tests help clarify the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/5130.html" rel="external">"Diagnosis of myasthenia gravis"</a> and  <a class="medical medical_review" href="/z/d/html/5174.html" rel="external">"Lambert-Eaton myasthenic syndrome: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5509.html" rel="external">"Botulism"</a>.)</p><p class="headingAnchor" id="H603783790"><span class="h2">Muscle disorders</span><span class="headingEndMark"> — </span>Acute polymyositis, critical illness myopathy, and critical illness neuropathy can mimic GBS. The myopathy and neuropathy of critical illness present as an acute paralysis, typically in patients receiving intensive care. High-dose intravenous glucocorticoids, neuromuscular blocking drugs, sepsis, and multiorgan failure are thought to play an important role, but the pathophysiology is not well understood. (See  <a class="medical medical_review" href="/z/d/html/5144.html" rel="external">"Neuromuscular weakness related to critical illness"</a>.)</p><p class="headingAnchor" id="H2786218774"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114912.html" rel="external">"Society guideline links: Guillain-Barré syndrome"</a>.)</p><p class="headingAnchor" id="H3084071"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/82816.html" rel="external">"Patient education: Guillain-Barré syndrome (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H3392812"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis </strong>– Guillain-Barré syndrome (GBS) is often triggered by an antecedent infection that evokes an immune response, which in turn reacts with peripheral nerve components because of the sharing of cross-reactive epitopes (molecular mimicry) to cause an acute polyneuropathy. <em>Campylobacter</em> infection is the most commonly identified precipitant of GBS. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>– GBS is the most common cause of acute flaccid paralysis in healthy infants and children. The estimated annual incidence in children is 0.34 to 1.34 cases per 100,000. The incidence increases by approximately 20 percent with every 10-year increase in age beyond the first decade of life. Males are affected approximately 1.5 times more often than females. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>– The classic presentation of GBS begins with paresthesia in the toes and fingertips followed by lower extremity fairly symmetric weakness that may ascend over hours to days to involve the arms and, in severe cases, the muscles of respiration. Cranial nerve and autonomic dysfunction may also occur. (See <a class="local">'Neurologic symptoms'</a> above.)</p><p></p><p class="bulletIndent1">Most patients reach their clinical nadir within two to four weeks, with subsequent return of function over the course of weeks to months. (See <a class="local">'Clinical course'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Variant forms </strong>– GBS is a heterogeneous syndrome with several variant forms (see <a class="local">'Variant forms of Guillain-Barré syndrome'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute inflammatory demyelinating polyneuropathy is the most common form of GBS. It is due to demyelinating injury and typically presents with ascending limb paralysis. (See <a class="local">'Acute inflammatory demyelinating polyneuropathy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute motor or motor-sensory neuropathies represent typically severe forms of GBS due to axonal damage. (See <a class="local">'Acute axonal neuropathies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The Miller Fisher syndrome, Bickerstaff brainstem encephalitis, and pharyngeal-cervical-brachial weakness are forms of GBS characterized by eye movement abnormalities and ataxia and are associated with frequent seropositivity to antibodies against the GQ1b ganglioside. (See <a class="local">'GQ1b syndromes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other rare syndromes include presentations of primarily cranial nerve, sensory, or autonomic dysfunction. (See <a class="local">'Polyneuritis cranialis'</a> above and <a class="local">'Other variants'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– The clinical diagnosis of GBS is made in patients with typical features of progressive, mostly symmetric muscle weakness and absent or depressed deep tendon reflexes. The clinical diagnosis is supported by findings on diagnostic testing that suggest GBS and help exclude alternative diagnoses. Testing may include the following (see <a class="local">'Diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cerebrospinal fluid (CSF) may show an albuminocytologic dissociation, characterized by an elevated CSF protein (&gt;45 mg/dL) with a normal CSF white blood cell count. (See <a class="local">'Cerebrospinal fluid'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Electrodiagnostic studies may demonstrate abnormalities indicating demyelination including motor conduction block, slowing of motor and sensory nerve conduction, temporal dispersion, and prolonged distal latencies. Decreased amplitude of motor (and possibly sensory) responses may be seen in axonal forms of GBS. (See <a class="local">'Electrodiagnostic studies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Spinal MRI with administration of gadolinium frequently shows enhancement of the spinal nerve roots and cauda equina. (See <a class="local">'Magnetic resonance imaging'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antibodies against GQ1b, a ganglioside component of nerve, are present in many patients with Miller Fisher and similar syndromes. (See <a class="local">'Antibodies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis </strong>– Disorders of the central nervous system, peripheral nerve, neuromuscular junction, and muscle may have features that initially resemble GBS (<a class="graphic graphic_table graphicRef80040" href="/z/d/graphic/80040.html" rel="external">table 1</a>). However, the presentation, neurologic examination, clinical course, cerebrospinal fluid profile, and electrodiagnostic findings usually establish the diagnosis of GBS. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H806750381"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Robert Cruse, DO, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Leonhard SE, van der Eijk AA, Andersen H, et al. An International Perspective on Preceding Infections in Guillain-Barré Syndrome: The IGOS-1000 Cohort. Neurology 2022; 99:e1299.</a></li><li><a class="nounderline abstract_t">Hao Y, Wang W, Jacobs BC, et al. Antecedent infections in Guillain-Barré syndrome: a single-center, prospective study. Ann Clin Transl Neurol 2019; 6:2510.</a></li><li><a class="nounderline abstract_t">Gupta M, Monjazeb S, Rosser T, et al. A Case of Pediatric Guillain-Barré Syndrome After Respiratory Syncytial Virus Infection. Pediatr Neurol 2023; 146:129.</a></li><li><a class="nounderline abstract_t">Manaud A, Geraudie A, Viguier A, et al. Post-CMV Guillain-Barré Syndrome with Anti-GM2 Antibodies: Two Cases and a Review of the Literature. Neuropediatrics 2022; 53:235.</a></li><li><a class="nounderline abstract_t">Hanzawa F, Fuchigami T, Ishii W, et al. A 3-year-old boy with Guillain-Barré syndrome and encephalitis associated with Mycoplasma pneumoniae infection. J Infect Chemother 2014; 20:134.</a></li><li><a class="nounderline abstract_t">Matsui M, Shimizu M, Ioi A, et al. Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis and Guillain-Barre Syndrome in a 16-Month-Old Child. Child Neurol Open 2016; 3:2329048X15620641.</a></li><li><a class="nounderline abstract_t">Verity C, Stellitano L, Winstone AM, et al. Guillain-Barré syndrome and H1N1 influenza vaccine in UK children. Lancet 2011; 378:1545.</a></li><li><a class="nounderline abstract_t">Bardage C, Persson I, Ortqvist A, et al. Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. BMJ 2011; 343:d5956.</a></li><li><a class="nounderline abstract_t">Lee GM, Greene SK, Weintraub ES, et al. H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. Am J Prev Med 2011; 41:121.</a></li><li><a class="nounderline abstract_t">Jones HR Jr. Guillain-Barré syndrome: perspectives with infants and children. Semin Pediatr Neurol 2000; 7:91.</a></li><li><a class="nounderline abstract_t">Chung A, Deimling M. Guillain-Barré Syndrome. Pediatr Rev 2018; 39:53.</a></li><li><a class="nounderline abstract_t">Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011; 36:123.</a></li><li><a class="nounderline abstract_t">Morris AM, Elliott EJ, D'Souza RM, et al. Acute flaccid paralysis in Australian children. J Paediatr Child Health 2003; 39:22.</a></li><li><a class="nounderline abstract_t">Delannoy A, Rudant J, Chaignot C, et al. Guillain-Barré syndrome in France: a nationwide epidemiological analysis based on hospital discharge data (2008-2013). J Peripher Nerv Syst 2017; 22:51.</a></li><li><a class="nounderline abstract_t">Carroll JE, Jedziniak M, Guggenheim MA. Guillain-Barré syndrome. Another cause of the "floppy infant". Am J Dis Child 1977; 131:699.</a></li><li><a class="nounderline abstract_t">Buchwald B, de Baets M, Luijckx GJ, Toyka KV. Neonatal Guillain-Barré syndrome: blocking antibodies transmitted from mother to child. Neurology 1999; 53:1246.</a></li><li><a class="nounderline abstract_t">Luijckx GJ, Vles J, de Baets M, et al. Guillain-Barré syndrome in mother and newborn child. Lancet 1997; 349:27.</a></li><li><a class="nounderline abstract_t">Hahn AF. Guillain-Barré syndrome. Lancet 1998; 352:635.</a></li><li><a class="nounderline abstract_t">Ropper AH. The Guillain-Barré syndrome. N Engl J Med 1992; 326:1130.</a></li><li><a class="nounderline abstract_t">Evans OB, Vedanarayanan V. Guillain-Barré syndrome. Pediatr Rev 1997; 18:10.</a></li><li><a class="nounderline abstract_t">Jones HR. Childhood Guillain-Barré syndrome: clinical presentation, diagnosis, and therapy. J Child Neurol 1996; 11:4.</a></li><li><a class="nounderline abstract_t">Pier DB, Hallbergson A, Peters JM. Guillain-Barré syndrome in a child with pain: lessons learned from a late diagnosis. Acta Paediatr 2010; 99:1589.</a></li><li><a class="nounderline abstract_t">Roodbol J, de Wit MC, Walgaard C, et al. Recognizing Guillain-Barre syndrome in preschool children. Neurology 2011; 76:807.</a></li><li><a class="nounderline abstract_t">Korinthenberg R, Schessl J, Kirschner J. Clinical presentation and course of childhood Guillain-Barré syndrome: a prospective multicentre study. Neuropediatrics 2007; 38:10.</a></li><li><a class="nounderline abstract_t">Estrade S, Guiomard C, Fabry V, et al. Prognostic factors for the sequelae and severity of Guillain-Barré syndrome in children. Muscle Nerve 2019; 60:716.</a></li><li><a class="nounderline abstract_t">Nguyen DK, Agenarioti-Bélanger S, Vanasse M. Pain and the Guillain-Barré syndrome in children under 6 years old. J Pediatr 1999; 134:773.</a></li><li><a class="nounderline abstract_t">Roodbol J, Korinthenberg R, Venema E, et al. Predicting respiratory failure and outcome in pediatric Guillain-Barré syndrome. Eur J Paediatr Neurol 2023; 44:18.</a></li><li><a class="nounderline abstract_t">Dimario FJ Jr, Edwards C. Autonomic dysfunction in childhood Guillain-Barré syndrome. J Child Neurol 2012; 27:581.</a></li><li><a class="nounderline abstract_t">Maier H, Schmidbauer M, Pfausler B, et al. Central nervous system pathology in patients with the Guillain-Barré syndrome. Brain 1997; 120 ( Pt 3):451.</a></li><li><a class="nounderline abstract_t">Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990; 27 Suppl:S21.</a></li><li><a class="nounderline abstract_t">Kleyweg RP, van der Meché FG, Loonen MC, et al. The natural history of the Guillain-Barré syndrome in 18 children and 50 adults. J Neurol Neurosurg Psychiatry 1989; 52:853.</a></li><li><a class="nounderline abstract_t">Cole GF, Matthew DJ. Prognosis in severe Guillain-Barré syndrome. Arch Dis Child 1987; 62:288.</a></li><li><a class="nounderline abstract_t">Briscoe DM, McMenamin JB, O'Donohoe NV. Prognosis in Guillain-Barré syndrome. Arch Dis Child 1987; 62:733.</a></li><li><a class="nounderline abstract_t">Wong V. A neurophysiological study in children with Miller Fisher syndrome and Guillain-Barre syndrome. Brain Dev 1997; 19:197.</a></li><li><a class="nounderline abstract_t">Barzegar M, Toopchizadeh V, Maher MHK, et al. Predictive factors for achieving independent walking in children with Guillain-Barre syndrome. Pediatr Res 2017; 82:333.</a></li><li><a class="nounderline abstract_t">Lin JJ, Hsia SH, Wang HS, et al. Clinical variants of Guillain-Barré syndrome in children. Pediatr Neurol 2012; 47:91.</a></li><li><a class="nounderline abstract_t">Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med 2012; 366:2294.</a></li><li><a class="nounderline abstract_t">Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol 2019; 15:671.</a></li><li><a class="nounderline abstract_t">Arcila-Londono X, Lewis RA. Guillain-Barré syndrome. Semin Neurol 2012; 32:179.</a></li><li><a class="nounderline abstract_t">McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 1993; 33:333.</a></li><li><a class="nounderline abstract_t">Visser LH, Van der Meché FG, Van Doorn PA, et al. Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barré Study Group. Brain 1995; 118 ( Pt 4):841.</a></li><li><a class="nounderline abstract_t">Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995; 118 ( Pt 3):597.</a></li><li><a class="nounderline abstract_t">Reisin RC, Cersósimo R, García Alvarez M, et al. Acute "axonal" Guillain-Barré syndrome in childhood. Muscle Nerve 1993; 16:1310.</a></li><li><a class="nounderline abstract_t">Paradiso G, Tripoli J, Galicchio S, Fejerman N. Epidemiological, clinical, and electrodiagnostic findings in childhood Guillain-Barré syndrome: a reappraisal. Ann Neurol 1999; 46:701.</a></li><li><a class="nounderline abstract_t">Nagasawa K, Kuwabara S, Misawa S, et al. Electrophysiological subtypes and prognosis of childhood Guillain-Barré syndrome in Japan. Muscle Nerve 2006; 33:766.</a></li><li><a class="nounderline abstract_t">Nachamkin I, Arzarte Barbosa P, Ung H, et al. Patterns of Guillain-Barre syndrome in children: results from a Mexican population. Neurology 2007; 69:1665.</a></li><li><a class="nounderline abstract_t">Ho TW, Li CY, Cornblath DR, et al. Patterns of recovery in the Guillain-Barre syndromes. Neurology 1997; 48:695.</a></li><li><a class="nounderline abstract_t">Feasby TE, Gilbert JJ, Brown WF, et al. An acute axonal form of Guillain-Barré polyneuropathy. Brain 1986; 109 ( Pt 6):1115.</a></li><li><a class="nounderline abstract_t">Feasby TE, Hahn AF, Brown WF, et al. Severe axonal degeneration in acute Guillain-Barré syndrome: evidence of two different mechanisms? J Neurol Sci 1993; 116:185.</a></li><li><a class="nounderline abstract_t">Shahrizaila N, Yuki N. Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome. J Neurol Neurosurg Psychiatry 2013; 84:576.</a></li><li><a class="nounderline abstract_t">FISHER M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956; 255:57.</a></li><li><a class="nounderline abstract_t">Marks HG, Augustyn P, Allen RJ. Fisher's syndrome in children. Pediatrics 1977; 60:726.</a></li><li><a class="nounderline abstract_t">Chiba A, Kusunoki S, Obata H, et al. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 1993; 43:1911.</a></li><li><a class="nounderline abstract_t">Winer JB. Bickerstaff's encephalitis and the Miller Fisher syndrome. J Neurol Neurosurg Psychiatry 2001; 71:433.</a></li><li><a class="nounderline abstract_t">Odaka M, Yuki N, Hirata K. Anti-GQ1b IgG antibody syndrome: clinical and immunological range. J Neurol Neurosurg Psychiatry 2001; 70:50.</a></li><li><a class="nounderline abstract_t">Michev A, Musso P, Foiadelli T, et al. Bickerstaff Brainstem Encephalitis and overlapping Guillain-Barré syndrome in children: Report of two cases and review of the literature. Eur J Paediatr Neurol 2019; 23:43.</a></li><li><a class="nounderline abstract_t">Ropper AH. Unusual clinical variants and signs in Guillain-Barré syndrome. Arch Neurol 1986; 43:1150.</a></li><li><a class="nounderline abstract_t">Mogale KD, Antony JH, Ryan MM. The pharyngeal-cervical-brachial form of Guillain-Barré syndrome in childhood. Pediatr Neurol 2005; 33:285.</a></li><li><a class="nounderline abstract_t">Rousseff RT, Khuraibet AJ, Neubauer D. The "Child in the Barrel syndrome"--severe pharyngeal-cervical-brachial variant of Guillain-Barre Syndrome in a toddler. Neuropediatrics 2008; 39:354.</a></li><li><a class="nounderline abstract_t">Ropper AH. Further regional variants of acute immune polyneuropathy. Bifacial weakness or sixth nerve paresis with paresthesias, lumbar polyradiculopathy, and ataxia with pharyngeal-cervical-brachial weakness. Arch Neurol 1994; 51:671.</a></li><li><a class="nounderline abstract_t">Wakerley BR, Yuki N. Polyneuritis cranialis: oculopharyngeal subtype of Guillain-Barré syndrome. J Neurol 2015; 262:2001.</a></li><li><a class="nounderline abstract_t">Morosini A, Burke C, Emechete B. Polyneuritis cranialis with contrast enhancement of cranial nerves on magnetic resonance imaging. J Paediatr Child Health 2003; 39:69.</a></li><li><a class="nounderline abstract_t">Polo A, Manganotti P, Zanette G, De Grandis D. Polyneuritis cranialis: clinical and electrophysiological findings. J Neurol Neurosurg Psychiatry 1992; 55:398.</a></li><li><a class="nounderline abstract_t">Nass R, Chutorian A. Dysaesthesias and dysautonomia: a self-limited syndrome of painful dysaesthesias and autonomic dysfunction in childhood. J Neurol Neurosurg Psychiatry 1982; 45:162.</a></li><li><a class="nounderline abstract_t">Mericle RA, Triggs WJ. Treatment of acute pandysautonomia with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 1997; 62:529.</a></li><li><a class="nounderline abstract_t">Wicklein EM, Pfeiffer G, Yuki N, et al. Prominent sensory ataxia in Guillain-Barré syndrome associated with IgG anti-GD1b antibody. J Neurol Sci 1997; 151:227.</a></li><li><a class="nounderline abstract_t">van den Berg B, Fokke C, Drenthen J, et al. Paraparetic Guillain-Barré syndrome. Neurology 2014; 82:1984.</a></li><li><a class="nounderline abstract_t">Korinthenberg R, Trollmann R, Felderhoff-Müser U, et al. Diagnosis and treatment of Guillain-Barré Syndrome in childhood and adolescence: An evidence- and consensus-based guideline. Eur J Paediatr Neurol 2020; 25:5.</a></li><li><a class="nounderline abstract_t">Al-Hakem H, Doets AY, Stino AM, et al. CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome. Neurology 2023; 100:e2386.</a></li><li class="breakAll">Ropper AH, Wijdicks EFM, Truax BT. Guillain-Barré syndrome, FA Davis, Philadelphia 1991. p.57.</li><li><a class="nounderline abstract_t">Delanoe C, Sebire G, Landrieu P, et al. Acute inflammatory demyelinating polyradiculopathy in children: clinical and electrodiagnostic studies. Ann Neurol 1998; 44:350.</a></li><li><a class="nounderline abstract_t">Bradshaw DY, Jones HR Jr. Guillain-Barré syndrome in children: clinical course, electrodiagnosis, and prognosis. Muscle Nerve 1992; 15:500.</a></li><li><a class="nounderline abstract_t">Korinthenberg R, Mönting JS. Natural history and treatment effects in Guillain-Barré syndrome: a multicentre study. Arch Dis Child 1996; 74:281.</a></li><li><a class="nounderline abstract_t">Coşkun A, Kumandaş S, Paç A, et al. Childhood Guillain-Barré syndrome. MR imaging in diagnosis and follow-up. Acta Radiol 2003; 44:230.</a></li><li><a class="nounderline abstract_t">Yikilmaz A, Doganay S, Gumus H, et al. Magnetic resonance imaging of childhood Guillain-Barre syndrome. Childs Nerv Syst 2010; 26:1103.</a></li><li><a class="nounderline abstract_t">Mulkey SB, Glasier CM, El-Nabbout B, et al. Nerve root enhancement on spinal MRI in pediatric Guillain-Barré syndrome. Pediatr Neurol 2010; 43:263.</a></li><li><a class="nounderline abstract_t">Zuccoli G, Panigrahy A, Bailey A, Fitz C. Redefining the Guillain-Barré spectrum in children: neuroimaging findings of cranial nerve involvement. AJNR Am J Neuroradiol 2011; 32:639.</a></li><li><a class="nounderline abstract_t">Willison HJ, Veitch J, Paterson G, Kennedy PG. Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside. J Neurol Neurosurg Psychiatry 1993; 56:204.</a></li><li><a class="nounderline abstract_t">Rodriguez-Casero MV, Shield LK, Kornberg AJ. Subacute inflammatory demyelinating polyneuropathy in children. Neurology 2005; 64:1786.</a></li><li><a class="nounderline abstract_t">Oh SJ, Kurokawa K, de Almeida DF, et al. Subacute inflammatory demyelinating polyneuropathy. Neurology 2003; 61:1507.</a></li><li><a class="nounderline abstract_t">Ruts L, Drenthen J, Jacobs BC, et al. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology 2010; 74:1680.</a></li></ol></div><div id="topicVersionRevision">Topic 6235 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35981895" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : An International Perspective on Preceding Infections in Guillain-BarréSyndrome: The IGOS-1000 Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31714025" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Antecedent infections in Guillain-Barrésyndrome: a single-center, prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37481934" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A Case of Pediatric Guillain-BarréSyndrome After Respiratory Syncytial Virus Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35716658" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Post-CMV Guillain-BarréSyndrome with Anti-GM2 Antibodies: Two Cases and a Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24462436" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A 3-year-old boy with Guillain-Barrésyndrome and encephalitis associated with Mycoplasma pneumoniae infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28503601" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis and Guillain-Barre Syndrome in a 16-Month-Old Child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22035553" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Guillain-Barrésyndrome and H1N1 influenza vaccine in UK children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21994316" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21767718" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10914410" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Guillain-Barrésyndrome: perspectives with infants and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29292294" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Guillain-BarréSyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21422765" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Population incidence of Guillain-Barrésyndrome: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12542807" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Acute flaccid paralysis in Australian children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27991707" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Guillain-Barrésyndrome in France: a nationwide epidemiological analysis based on hospital discharge data (2008-2013).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/868825" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Guillain-Barrésyndrome. Another cause of the "floppy infant".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10522880" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Neonatal Guillain-Barrésyndrome: blocking antibodies transmitted from mother to child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8988121" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Guillain-Barrésyndrome in mother and newborn child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9746040" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1552914" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8993064" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8745378" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Childhood Guillain-Barrésyndrome: clinical presentation, diagnosis, and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20456276" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Guillain-Barrésyndrome in a child with pain: lessons learned from a late diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21357832" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Recognizing Guillain-Barre syndrome in preschool children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17607598" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical presentation and course of childhood Guillain-Barrésyndrome: a prospective multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31531862" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Prognostic factors for the sequelae and severity of Guillain-Barrésyndrome in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10356150" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pain and the Guillain-Barrésyndrome in children under 6 years old.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36931152" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Predicting respiratory failure and outcome in pediatric Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22241710" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Autonomic dysfunction in childhood Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9126057" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Central nervous system pathology in patients with the Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2194422" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Assessment of current diagnostic criteria for Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2769279" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The natural history of the Guillain-Barrésyndrome in 18 children and 50 adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3566320" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prognosis in severe Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3632024" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prognosis in Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9134191" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A neurophysiological study in children with Miller Fisher syndrome and Guillain-Barre syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28422939" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Predictive factors for achieving independent walking in children with Guillain-Barre syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22759683" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clinical variants of Guillain-Barrésyndrome in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22694000" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31541214" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Diagnosis and management of Guillain-Barrésyndrome in ten steps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23117942" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8489203" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7655882" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Guillain-Barrésyndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-BarréStudy Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7600081" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Guillain-Barrésyndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8232386" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Acute "axonal" Guillain-Barrésyndrome in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10553986" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Epidemiological, clinical, and electrodiagnostic findings in childhood Guillain-Barrésyndrome: a reappraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16506153" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Electrophysiological subtypes and prognosis of childhood Guillain-Barrésyndrome in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17898327" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Patterns of Guillain-Barre syndrome in children: results from a Mexican population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9065550" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Patterns of recovery in the Guillain-Barre syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3790970" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : An acute axonal form of Guillain-Barrépolyneuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8336165" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Severe axonal degeneration in acute Guillain-Barrésyndrome: evidence of two different mechanisms?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22984203" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13334797" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/917636" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Fisher's syndrome in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8413947" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barrésyndrome: clinical and immunohistochemical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11561023" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Bickerstaff's encephalitis and the Miller Fisher syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11118247" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Anti-GQ1b IgG antibody syndrome: clinical and immunological range.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30502045" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Bickerstaff Brainstem Encephalitis and overlapping Guillain-Barrésyndrome in children: Report of two cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2946281" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Unusual clinical variants and signs in Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16194730" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The pharyngeal-cervical-brachial form of Guillain-Barrésyndrome in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19569002" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The "Child in the Barrel syndrome"--severe pharyngeal-cervical-brachial variant of Guillain-Barre Syndrome in a toddler.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8018039" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Further regional variants of acute immune polyneuropathy. Bifacial weakness or sixth nerve paresis with paresthesias, lumbar polyradiculopathy, and ataxia with pharyngeal-cervical-brachial weakness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25712542" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Polyneuritis cranialis: oculopharyngeal subtype of Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12542820" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Polyneuritis cranialis with contrast enhancement of cranial nerves on magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1318358" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Polyneuritis cranialis: clinical and electrophysiological findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7069429" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Dysaesthesias and dysautonomia: a self-limited syndrome of painful dysaesthesias and autonomic dysfunction in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9153616" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Treatment of acute pandysautonomia with intravenous immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9349681" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Prominent sensory ataxia in Guillain-Barrésyndrome associated with IgG anti-GD1b antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24808021" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Paraparetic Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31941581" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Diagnosis and treatment of Guillain-BarréSyndrome in childhood and adolescence: An evidence- and consensus-based guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37076309" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-BarréSyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37076309" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-BarréSyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9749601" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Acute inflammatory demyelinating polyradiculopathy in children: clinical and electrodiagnostic studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1565119" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Guillain-Barrésyndrome in children: clinical course, electrodiagnosis, and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8669925" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Natural history and treatment effects in Guillain-Barrésyndrome: a multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12694112" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Childhood Guillain-Barrésyndrome. MR imaging in diagnosis and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20556395" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Magnetic resonance imaging of childhood Guillain-Barre syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20837305" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Nerve root enhancement on spinal MRI in pediatric Guillain-Barrésyndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21292802" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Redefining the Guillain-Barréspectrum in children: neuroimaging findings of cranial nerve involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8437011" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15911813" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Subacute inflammatory demyelinating polyneuropathy in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14663033" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Subacute inflammatory demyelinating polyneuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20427754" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
